Cirrhosis is the final common pathway of progressive chronic liver injury — a stage in which healthy liver tissue has been replaced by permanent scar tissue (fibrosis) that distorts the liver's internal architecture and progressively impairs its function. Although advanced cirrhotic scarring itself cannot be reversed, progression can often be halted with treatment of the underlying cause, and early-stage cirrhosis carries a far better prognosis than late decompensated disease.
Cirrhosis is the end stage of every progressive liver disease — it can arise from fatty liver disease (MASLD/MASH), chronic viral hepatitis, alcohol-associated liver disease, and numerous other causes. Its most dangerous downstream consequences are portal hypertension — the elevated portal venous pressure that drives ascites, variceal bleeding, and splenomegaly — and hepatocellular carcinoma (HCC), which arises in cirrhotic liver at a rate of 1–5% per year, making surveillance imaging every 6 months a mandatory component of cirrhosis care. MRI is both the most accurate tool for staging cirrhosis severity and the most sensitive study for detecting early HCC when curative treatment is still possible.
Causes
Chronic liver injury.
Cirrhosis is the endpoint of sustained liver injury from any cause — the common final pathway in which cycles of hepatocyte death, inflammation, and attempted regeneration produce progressive collagen deposition and architectural distortion. The most common causes in the United States are alcohol-associated liver disease (ALD), metabolic dysfunction-associated steatotic liver disease (MASLD/MASH) — now the fastest-growing cause of cirrhosis and liver transplant waitlist listing — and chronic viral hepatitis (hepatitis C, which is now curable with direct-acting antivirals, and hepatitis B, which is suppressible with antiviral therapy). In patients with hepatitis C who achieve sustained virologic response (cure), the rate of fibrosis progression halts and some degree of fibrosis regression is possible.
Other causes.
Less common but important causes include autoimmune hepatitis (immune-mediated hepatocyte destruction that responds to immunosuppression), primary biliary cholangitis (PBC — autoimmune destruction of small bile ducts), primary sclerosing cholangitis (PSC — inflammatory stricturing of larger bile ducts, strongly associated with inflammatory bowel disease and cholangiocarcinoma risk), hereditary hemochromatosis (iron overload causing hepatocyte toxicity, treatable with phlebotomy), Wilson disease (copper accumulation), alpha-1 antitrypsin deficiency, certain medications (methotrexate, amiodarone), and chronic right-sided heart failure causing congestive hepatopathy. Cryptogenic cirrhosis — where no cause is identified — likely represents unrecognized MASLD or burned-out autoimmune hepatitis in many cases.
Symptoms
Compensated cirrhosis — where the liver retains sufficient functional reserve — often produces no symptoms and is discovered incidentally on bloodwork showing a low platelet count (from hypersplenism) or mildly abnormal liver enzymes, or on imaging showing a nodular liver contour. The transition from compensated to decompensated cirrhosis marks a critical prognostic threshold — median survival falls from over 12 years in compensated disease to 2 years in decompensated disease. Decompensation events include ascites (the most common first decompensation, caused by portal hypertension and reduced albumin), variceal hemorrhage (acute bleeding from esophageal or gastric varices that carry 15–20% mortality per episode), hepatic encephalopathy (confusion, asterixis, and coma from ammonia accumulation), jaundice from failed bilirubin conjugation and excretion, spontaneous bacterial peritonitis (infection of ascitic fluid), and hepatorenal syndrome (acute kidney failure in the setting of advanced liver disease).
Diagnosis
Evaluation combines blood tests, imaging, and in selected cases liver biopsy. The FIB-4 index, serum albumin, bilirubin, INR, and platelet count together provide strong indirect evidence of cirrhosis and its severity. Ultrasound is frequently the initial imaging study and may show a nodular liver surface, coarsened parenchymal echotexture, an enlarged caudate lobe, splenomegaly, and ascites — but is limited in detecting early cirrhosis and small liver nodules.
An MRI of the abdomen is the most comprehensive noninvasive imaging study for cirrhosis evaluation. MRI characterizes the full spectrum of cirrhotic findings: a nodular liver surface and heterogeneous parenchymal signal from regenerative and dysplastic nodules, caudate lobe hypertrophy, right lobe atrophy, splenomegaly, varices, ascites, and signs of portal hypertension. MR elastography (MRE) quantifies liver stiffness with stiffness values above 4–5 kPa suggesting advanced fibrosis and above 6–7 kPa consistent with cirrhosis — providing objective staging without biopsy. Most critically, MRI using the LI-RADS (Liver Imaging Reporting and Data System) framework is the most sensitive imaging tool for detecting early hepatocellular carcinoma — the characteristic arterial phase hyperenhancement with portal venous or delayed phase washout appearance (LI-RADS 5 = definitely HCC) allows diagnosis without biopsy in cirrhotic patients, enabling prompt treatment while the tumor is still small and surgically resectable or ablatable.
Classification
Cirrhosis is classified by functional status and by validated scoring systems that guide transplant prioritization.
- Compensated cirrhosis: Liver function preserved; no prior decompensation events. Median survival exceeds 12 years. The primary management goals are treating the underlying cause, preventing decompensation, and screening for HCC every 6 months.
- Decompensated cirrhosis: One or more decompensation events (ascites, variceal bleeding, encephalopathy, jaundice) have occurred. Median survival approximately 2 years without transplant. Liver transplant evaluation is indicated.
The Child-Pugh score (incorporating bilirubin, albumin, INR, ascites, and encephalopathy) stratifies into Class A (compensated, best prognosis), B (moderate), and C (decompensated, worst prognosis). The MELD score (Model for End-Stage Liver Disease — calculated from creatinine, bilirubin, and INR) is used by UNOS to prioritize liver transplant waitlist allocation — higher MELD scores receive organ offers first.
Treatments
Treatment focuses on halting the underlying injury, managing complications, screening for cancer, and pursuing transplantation for eligible patients with advanced disease.
Treatment of the underlying cause: Complete and sustained alcohol abstinence can halt ALD progression and allow partial fibrosis regression. Direct-acting antiviral therapy cures hepatitis C in over 95% of patients with a 12-week oral regimen — even patients with established cirrhosis benefit substantially, with reduced HCC risk and improved liver function. Tenofovir or entecavir suppresses hepatitis B replication and slows progression. Weight loss and metabolic management for MASLD/MASH can improve fibrosis stage. Immunosuppression (prednisone, azathioprine) controls autoimmune hepatitis. Phlebotomy for hemochromatosis prevents further iron-mediated injury.
Management of complications.
Ascites is managed with dietary sodium restriction (less than 2 g/day) and diuretics (spironolactone and furosemide); refractory ascites requires repeated large-volume paracentesis or transjugular intrahepatic portosystemic shunt (TIPS) placement. Non-selective beta-blockers (propranolol, carvedilol) and endoscopic variceal band ligation reduce the risk of first and recurrent variceal bleeding. Hepatic encephalopathy is treated with lactulose (to reduce ammonia absorption) and rifaximin (a non-absorbable antibiotic reducing gut ammonia-producing bacteria). Spontaneous bacterial peritonitis requires urgent intravenous antibiotics and albumin infusion. Vaccination against hepatitis A, B, influenza, and pneumococcus reduces infection-related morbidity.
Cancer surveillance.
Ultrasound every 6 months — or MRI when ultrasound is suboptimal due to obesity or poor visualization — is the standard surveillance protocol for hepatocellular carcinoma in all patients with cirrhosis. Early detection when tumors are under 2 cm dramatically improves the chance of curative treatment with ablation, resection, or transplant. AFP (alpha-fetoprotein) is measured alongside imaging as an adjunctive tumor marker, though it lacks sensitivity for small HCC.
Liver transplantation.
Liver transplantation is the only definitive treatment for end-stage cirrhosis and offers a potential cure. The Milan criteria — one HCC nodule up to 5 cm, or up to three nodules each up to 3 cm, without vascular invasion or extrahepatic spread — define transplant eligibility for patients with HCC in the setting of cirrhosis. Five-year survival after liver transplantation for cirrhosis exceeds 70% at experienced centers.
Nutrition and general care.
Patients with cirrhosis have high protein requirements (1.2–1.5 g/kg/day) to prevent sarcopenia, which worsens prognosis and increases post-transplant complications. Branched-chain amino acids may benefit patients with encephalopathy who cannot tolerate standard protein intake. Avoidance of hepatotoxic medications, herbal supplements, and over-the-counter NSAIDs (which reduce renal perfusion in cirrhotic patients) is essential.
Get an MRI to Confirm Your Diagnosis
Before surgical planning or starting treatment, a clear MRI diagnosis ensures the right path forward. First Look MRI offers self-pay Abdomen MRI scans — no doctor's order or insurance required — at our locations in Georgia, Texas, and Colorado.